ALK-POSITIVE NSCLC
Clinical trials for ALK-POSITIVE NSCLC explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE NSCLC trials appear
Sign up with your email to follow new studies for ALK-POSITIVE NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis early-stage trial tests whether combining two drugs, ceritinib and nivolumab, is safe and effective for people with a specific genetic subtype of advanced lung cancer called ALK-positive NSCLC. About 57 adults with stage IIIB or IV disease will receive the combination. The m…
Matched conditions: ALK-POSITIVE NSCLC
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
Knowledge-focused OngoingThis study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…
Matched conditions: ALK-POSITIVE NSCLC
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC